Comparison of somatic mutation calling methods in amplicon and whole exome sequence data by Huilei Xu et al.
Xu et al. BMC Genomics 2014, 15:244
http://www.biomedcentral.com/1471-2164/15/244RESEARCH ARTICLE Open AccessComparison of somatic mutation calling methods
in amplicon and whole exome sequence data
Huilei Xu, John DiCarlo, Ravi Vijaya Satya, Quan Peng and Yexun Wang*Abstract
Background: High-throughput sequencing is rapidly becoming common practice in clinical diagnosis and cancer
research. Many algorithms have been developed for somatic single nucleotide variant (SNV) detection in matched
tumor-normal DNA sequencing. Although numerous studies have compared the performance of various algorithms
on exome data, there has not yet been a systematic evaluation using PCR-enriched amplicon data with a range of
variant allele fractions. The recently developed gold standard variant set for the reference individual NA12878 by
the NIST-led “Genome in a Bottle” Consortium (NIST-GIAB) provides a good resource to evaluate admixtures with
various SNV fractions.
Results: Using the NIST-GIAB gold standard, we compared the performance of five popular somatic SNV calling
algorithms (GATK UnifiedGenotyper followed by simple subtraction, MuTect, Strelka, SomaticSniper and VarScan2)
for matched tumor-normal amplicon and exome sequencing data.
Conclusions: We demonstrated that the five commonly used somatic SNV calling methods are applicable to both
targeted amplicon and exome sequencing data. However, the sensitivities of these methods vary based on the
allelic fraction of the mutation in the tumor sample. Our analysis can assist researchers in choosing a somatic SNV
calling method suitable for their specific needs.Background
Somatic point mutation calling from matched tumor-
normal patient samples is a critical step for cancer gen-
ome characterization and clinical genotyping [1,2]. Over
the last few years, next-generation sequencing (NGS)
has become a popular strategy for genotyping, enabling
more precise mutation detection compared to traditional
methods due to its high resolution and high throughput
[3]. Nevertheless, detecting somatic mutations is still
challenging, especially for low-allelic-fraction variants
caused by tumor heterogeneity, copy number alteration,
and sample degradation [4-6]. Errors in base calling and
read alignment present additional challenges for achiev-
ing sensitive and specific somatic variant calls. In recent
years, several methods have been developed to enhance
somatic mutation calling accuracy [7-11]. In general,
these methods belong to two families: (1) independent
analysis for tumor and normal datasets from an individ-
ual followed by SNV type classification using a statistical* Correspondence: yexun.wang@qiagen.com
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unless otherwise stated.significance test or simple subtraction (e.g. [12]); (2) sim-
ultaneous analysis for matched tumor and normal data-
sets using joint probability-based statistical approaches,
e.g. SomaticSniper [9] and Strelka [11]. In general, agree-
ment among different algorithms is relatively low
[13,14], making selection of candidate SNVs for further
validation difficult. This disagreement is likely partially
due to different error models and prior assumptions
underlying each algorithm.
In light of these challenges, there is a need to system-
atically evaluate the performance of different SNV
calling algorithms to help guide best practices in the re-
search community. Recently, several independent studies
compared somatic SNV calling tools [15-17]. For ex-
ample, Roberts et al. [15] compared the performance of
VarScan, SomaticSniper, JointSNVMix2, and Strelka in
detecting SNVs from matched cancer-normal Illumina
exome sequencing of a chronic myeloid leukemia pa-
tient. They reported a large difference in called variant
sets among algorithms. In a separate study, Wang et al.
[17] evaluated 6 tools (EBCall, JointSNVMix, MuTect,
SomaticSniper, Strelka, and VarScan2) on tumor-normalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sequencing data. According to their evaluation, MuTect
achieved the highest sensitivity for calling low-allelic-
fraction somatic variants. Most of these studies utilized
publically available exome data from hybridization cap-
ture enrichment, and some used additional validation
data from alternative technologies. Complimentarily,
Spencer et al. [16] assessed SAMtools, Genome Analysis
Toolkit (GATK), VarScan2, and SPLINTER in detecting
low-allelic-fraction variants from synthetic mixtures of
targeted hybridization capture sequencing reads. They
reported that VarScan2 achieved the highest sensitivity
but with a high false positive rate, whereas SPLINTER
yielded both high sensitivity and specificity.
Exome capture sequencing is typically limited to ~60x
read depth (due to cost), and therefore using exome
reads limits the potential to detect low-allelic-fraction
SNVs in the sample, especially those at less than 5%. De-
tecting low-allelic-fraction SNVs in the sample is often
important for early diagnosis, prevention of drug resist-
ance, and detection of residual tumors. Targeted panel
sequencing has been widely used to increase SNV detec-
tion sensitivity by achieving a much higher median read
depth (>500x), even on a bench top sequencer [18,19].
Among the different enrichment methods available for
targeted sequencing, PCR amplicon-based enrichment
has been widely popular for small- to medium-sized
gene panels due to its low input requirement, simple
protocol, fast turnaround time, and good performance
on FFPE samples. While there are differences between
read properties from PCR amplicon sequencing and ex-
ome sequencing, many of which could affect SNV call-
ing, there has not yet been a detailed comparison of
SNV calling algorithms using reads from PCR amplicon
sequencing. In addition to higher read depth, reads from
PCR amplicons have more uniformly defined ends, more
PCR duplication, and may contain more amplification
bias. Because many variant calling algorithms were de-
veloped using whole genome or exome data, the ques-
tion remains of whether performance differs when these
algorithms are applied to amplicon sequencing data.
Another challenge in comparing variant calling methods
is to identify a set of true positive and true negative vari-
ants in the sample, ideally at various allele fractions. This
task is not straightforward, due to the lack of sufficient
available validation data. One standard assessment method
is to check the overlap between variant sets as a way to as-
sess the concordance and discrepancies among different
calling methods. Alternatively, some researchers have ran-
domly chosen a few candidates for Sanger sequencing or
used SNP arrays for validation. However, Sanger sequen-
cing involves high cost and labor, making the generation
of large-scale validation data difficult. In addition, some of
the low-allelic-fraction SNVs are very difficult to validateby Sanger sequencing or SNP array due to the detection
sensitivity of these technologies (typically insufficient for
variants below 20% fraction). To overcome these limita-
tions, the NIST-led “Genome in a Bottle” Consortium
(NIST-GIAB) [20] developed a community resource of
high-confidence variants for the reference individual
NA12878. From the July 17, 2013 data release, the NIST-
GIAB standard is an integration of 12 datasets generated
using 5 different sequencing platforms, with the reads
aligned using 7 different aligners, and variants called using
3 different variant callers. The availability of the NA12878
reference sample (from Coriell Institute) along with a
high-confidence variant set facilitates empirical evaluation
of all steps in NGS analysis: enrichment, library prepar-
ation, sequencing, alignment, and variant calling. The
NIST-GIAB NA12878 variant standard is the basis
of emerging tools such as GCAT (http://www.bioplanet.
com/gcat), which provides a community platform for
comparing variant calling approaches.
In order to evaluate the performance of popular SNV
callers on targeted amplicon sequencing reads, especially
for low-allelic-fraction SNVs, we mixed reference DNA
from NA12878 with DNA from another 1,000 Genomes
Project sample (NA19129) at various ratios, thus creating
virtual tumor-normal samples with NA12878 “tumor”
variant frequencies ranging from 4% to 100%. We then
subjected the dilution series samples to multiplex PCR-
based enrichment and Illumina MiSeq sequencing. Here
we present a comparison of 5 somatic SNV callers using
targeted amplicon sequencing from these virtual tumor-
normal samples against the NIST-GIAB gold standard
variant set. To explore possible performance differences of
the SNV callers on amplicon versus exome sequencing
data, we also did a similar in silico dilution series analysis
using publicly available exome data from NA12878. Our
results demonstrate the strengths and weaknesses of each
method in calling somatic SNVs at diverse levels of allelic
fraction, and also the value of the newly established NIST-
GIAB gold standard in facilitating such comparisons.
Results
Comparison of somatic point mutation calling methods in
the benchmark amplicon sequencing data
Our goal was to evaluate the performance of somatic
SNV detection methods from matched tumor-normal
samples using amplicon sequencing. For this purpose,
we generated a dilution series of samples with 0%, 8%,
16%, 36%, and 100% NA12878 mixed in the control
NA19129, to mimic production of artificial tumor sam-
ple paired with the 100% NA19129 background as the
artificial normal sample. Because the majority of variants
in the gold standard are heterozygous (the ratio of het-
erozygous to homozygous alternative variants is 5 to 1),
the main allele fractions we evaluated are 4%, 8%, 18%,
Xu et al. BMC Genomics 2014, 15:244 Page 3 of 10
http://www.biomedcentral.com/1471-2164/15/244and 50%. Therefore, we labelled the samples as C04 (4%
as the expected heterozygous variant allele), C08 (8%),
C18 (18%), and C50 (50%) in the following descriptions
and results. We used QIAGEN’s GeneRead DNAseq
Comprehensive Cancer Gene Panel (CCP, Version 1) for
enrichment and library construction in triplicate [21].
Then we sequenced the samples for the 124 CCP genesFigure 1 Distribution of variant allele fraction of NA12878 SNV sites.
(A) amplicon sequencing experimental dilution series of one replicate over
series over the exome region of interest. The x-axis represents the variant a
Homozygous alternate alleles in NA12878 are shown in red, and heterozygusing an Illumina MiSeq sequencer. The median cover-
age for each triplicate was between 500x and 700x. First,
we examined the observed minor allele fraction of
NA12878 “somatic” variants to verify the mixture con-
centration (Figure 1A). Generally, both heterozygous
and homozygous alternate allele frequencies fell within
the expected range. To systematically evaluate variantDistribution of NA12878 unique SNV sites allele fraction of
the CCP region of interest and (B) exome sequencing in silico dilution
llele fraction and the y-axis represents the number of sites.
ous alternate alleles are shown in blue.
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alignment and preprocessing steps before variant calling
(see Methods). The resulting BAM files were then used
as input to five somatic mutation calling methods,
including (1) MuTect, (2) GATK UnifiedGenotyper [22]
followed by simple subtraction (or simply referred as
“NaiveSubtract” in this article), (3) SomaticSniper, (4)
Strelka, and (5) VarScan2 (Methods and Table 1). All
methods are open-source algorithms except for the
“NaiveSubtract” method, which calls SNVs by identifying
the variants present in the “tumor” sample VCF file but
not in the “normal” sample VCF file. The variants set for
“tumor” and “normal” samples were called independ-
ently using GATK UnifiedGenotyper.
We assessed the sensitivity and specificity of each vari-
ant calling algorithm on each virtual tumor sample using
the NIST-GIAB gold standard variant set (Version 2.15).
Our analysis region excludes sites where NA19129 is not
a homozygous reference (for region of interest (ROI),
see Additional file 1: Table S1). We compared somatic
SNV calling performance at various “tumor purity” levels
(Figure 2A). At the lowest purity level, the highest sensi-
tivity was achieved by Strelka (0.851 ± 0.05) under the
settings recommended by its authors. MuTect, with its
default setting under HC mode (high-confidence mode),
achieved lower sensitivity than Strelka (about 0.60),
although this might in part be due to MuTect being
tuned for higher specificity. In terms of specificity, be-
cause we expect that the number of false positives de-
tected does not depend on the fraction of NA12878 in
the “tumor” sample, we calculated the false positive rate
by treating each single virtual tumor sample as a repli-
cate (12 total replicates). MuTect produced the lowest
false positive rate, whereas the other four methods pro-
vided similar levels of specificity (Figure 3A). Overall,
Strelka and MuTect are capable of detecting candidate
somatic SNVs at sites of low allelic fraction. This prop-
erty is of key importance for studying cancer subclones
and highly heterogeneous tumor samples. The sensitivity
of all methods increased in samples with a larger frac-
tion of NA12878. As shown in Figure 2A, all of the
methods perform fairly well for calling sites in the 100%
NA12878 sample. The impact of algorithm selection be-
came weaker for high-allelic-fraction somatic SNV call-
ing. VarScan2, among other traditional approaches, callsTable 1 List of somatic SNV calling methods and versions
Methods Version Reference




VarScan2 v2.3.6 [8]variants from each sample independently to estimate the
difference between control and disease samples. VarS-
can2 did not perform well for calling low-allelic-fraction
variants. Though VarScan2 can achieve a higher sensi-
tivity of 0.5 if its minimum allele fraction threshold is
lowered to 0.05, it then generates a much higher false
positive rate (300 false positives per Mb). For SomaticS-
niper, examination of the distribution of somatic scores
(data not shown) indicates that a cut-off of 20 can re-
duce false positives without compromising sensitivity.
Therefore, we added an ad hoc post-calling filtering step
with a somatic score cut-off of 20. Nevertheless, Soma-
ticSniper gave low sensitivity in low-allelic-fraction variant
calling, even though it achieves the highest sensitivity for
the 100% “pure tumor” sample. As for NaiveSubtract, our
results indicate that GATK UnifiedGenotyper can detect
very few variants at <8% allelic fraction. Therefore, when
used with PCR amplicon sequencing data with a median
read depth above 500x, Strelka and MuTect can call vari-
ants at all allelic fraction levels, whereas NaiveSubtract,
VarScan2, and SomaticSniper provide less sensitivity for
calling somatic SNVs of low allelic fraction, at least when
using their default settings. Consistent with [15], the stat-
istical model-based methods such as MuTect and Strelka
are more efficient, because they consider the correlations
between tumor-normal pairs and calculate the joint prob-
abilities of the genotype pairs.
Trade-offs between sensitivity and specificity for MuTect
and Strelka
Next we further examined the difference between
MuTect and Strelka. We chose to focus on these two
methods out of the five because they achieved signifi-
cantly higher sensitivity at the lowest SNV fraction with
similar or lower false positive rates than the other
methods. Previous studies have compared the perform-
ance of MuTect and Strelka in exome sequencing [7]. As
shown in Figures 2A and 3A for our amplicon sequen-
cing, Strelka achieved significantly better sensitivity than
MuTect under the recommended settings, but at the ex-
pense of a much higher false positive rate. The question
remains whether this difference would disappear by fur-
ther tuning the algorithms or it represents a true differ-
ence in performance. We examined the performance
trade-offs by varying cut-offs for the MuTect somatic
variant log-likelihood score and the Strelka quality score,
which reflect the joint probability of a somatic variant
and a normal genotype (Figure 4). While differences
exist between the two methods when using default set-
tings, we observed that they can achieve very similar
sensitivity/specificity trade-offs for lower SNV fractions
(C04 and C08) by tuning the core statistics parameter
and/or post-calling filters. However, the disparity be-
tween the methods remains at higher SNV fractions
Figure 2 Sensitivity of somatic SNV calling methods. The x-axis represents the methods and the y-axis represents sensitivity for (A) amplicon
sequencing data and (B) exome sequencing data. C04, C08, C18, and C50 represent mixing concentrations of 8%, 16%, 36%, and 100% samples
in amplicon sequencing data, and median allele fractions of 4%, 8%, 18%, and 50% for NA12878 unique heterozygous SNVs in in silico mixture
exome sequencing data over the region of interest. For the amplicon sequencing data, columns represent the mean and error bars represent the
standard deviation of the triplicate.
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tivity with a lower false positive rate. One possible ex-
planation for this continuing difference is the sampling
limitation for C04 and C08. Low-allelic-fraction SNVs
may not be sampled sufficiently during enrichment and
sequenced with adequate read depth, potentially limiting
our ability to assess performance differences in C04 and
C08. Alternatively, more sequencing errors and dimers
may be called as variants at greater abundance levels.
Overall, our analysis demonstrated that the algorithms
differ in sensitivity and specificity, and users should
therefore select their algorithm depending on which per-
formance characteristic is the highest priority.Figure 3 Specificity of somatic SNV calling methods. The x-axis represe
the region of interest, for (A) the amplicon sequencing dilution series tripli
NA12878 sample.Comparison of somatic point mutation calling methods in
exome sequencing data
Because most matched tumor-normal variant callers
were developed using exome sequencing data, we next
assessed whether their respective performance differs be-
tween high-read-depth PCR-based amplicon sequencing
and low-read-depth hybridization capture-based exome
sequencing. The two approaches have different read
depths and amplification bias, which could affect variant
calling accuracy. Therefore, we compared the abilities of
the aforementioned five methods to accurately call som-
atic SNVs in exome sequencing data. For exome reads,
we chose a different Yoruba individual (NA18489) thannts the methods and the y-axis represents false positives per Mb over
cate (mean ± standard deviation); (B) exome sequencing 100%
Figure 4 ROC-like curves summarizing sensitivity and specificity of MuTect and Strelka. Sensitivity and FPR (per Mb) plots using various
values of MuTect LOD threshold and Strelka QSS_NT threshold generated from one dilution series replicate of amplicon sequencing data. Original
thresholds in each final model are marked with black circles (corresponding to outputs in Figure 2).
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exome sequencing reads for NA18489 were generated
using the same capture procedure used for NA12878.
The exome sequencing data of NA12878 and NA18489
are publicly available, as part of the 1,000 Genomes Pro-
ject (Additional file 1: Table S2). We downsampled the
preprocessed BAM files and, in silico, mixed the result-
ing subsets of reads to desired “tumor” sample purities.
The resulting in silico mixture series is diluted in the
same way as the amplicon sequencing experimental dilu-
tion series: at NA12878 unique heterozygous (homozy-
gous alternative) variant positions over the region of
interest, the median variant allele fraction is 4% (8%), 8%
(16%), 18% (36%) and 50% (100%), respectively (Figure 1B).
Then we applied the five variant calling methods on the insilico matched “tumor-normal” exome sequencing pairs
over the region of interest (Additional file 1: Table S1).
Additionally, we checked performance results from the
CCP region of the exome sequencing data and verified
that there are no special advantages/disadvantages to
the CCP region relative to the exome capture region
(data not shown).
Overall, the sensitivity ranking of each method is com-
parable with what was achieved in targeted amplicon se-
quencing data (Figure 2). For the exome data, MuTect
and Strelka detected more somatic mutations than the
other methods. MuTect gave the best sensitivity among
lower concentrations and Strelka gave the second-best
sensitivity. Results from the MuTect publication [7]
show that for variants at 5% abundance, MuTect’s
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depth between 30x and 60x, whereas Strelka, used with
standard settings, detected between 0.16 and 0.40 in the
same sequencing depth range. Therefore, our present
observations are consistent with this previous study.
SomaticSniper, VarScan2, and NaiveSubtract still yielded
low sensitivity in detecting lower-allelic-fraction somatic
SNVs. In addition, consistent with what was observed in
the targeted sequencing data, all methods achieved high
sensitivity in the high-allelic-fraction tumor samples.
We next assessed specificity using only the C50 sam-
ple in order not to introduce potential artifacts arising
from the in silico mixing. MuTect and Strelka achieved
the highest specificity (Figure 3). All methods except
NaiveSubtract showed a lower false positive rate com-
pared to amplicon sequencing. This is could be partially
due to the fact that all the methods were primarily de-
signed on genome-wide sequencing data or exome data
and therefore better control false positives in that data
type. Furthermore, since false positive rate is positively
correlated with sequencing read depth [7], the greater
number of reads generated by amplicon sequencing
technology may yield more false positives.
Discussion
As the first step in analyzing cancer sequencing data, de-
tecting variants with high sensitivity and specificity is of
great importance. Our results highlight the differences
in performance between five algorithms when used with
targeted amplicon versus exome sequencing data. When
analyzing different types of data, use of different algo-
rithms may be appropriate. For example, methods using
a hypothesis of Poisson/binomial distribution of alter-
nate allele read depth would deviate from actual exome
sequencing data, which display a notable overdispersion
in the distribution of alternate allele read depth [23]. In
terms of sensitivity, we observed that the five algorithms
perform better in calling low-allelic-fraction variants
from amplicon sequencing data than from exome data,
probably due to the higher sequencing depth in the
former. In fact, when the amplicon sequencing data were
in silico downsampled to the same sequencing depth as
the exome data, the sensitivity from all algorithms
dropped and declined more significantly in C04 and
C08, while the relative performance ranking remained
the same (data not shown). On the other hand, since se-
quencing read depth is among the factors affecting false
positive rate, most algorithms generate more false posi-
tives in amplicon sequencing data. However, we also
demonstrate through Strelka and MuTect that further
tuning the “joint probability” score away from the de-
fault setting can reduce the false positives in amplicon
sequencing to levels similar to that for exome sequen-
cing, without substantially compromising sensitivity. Insummary, the relative performance ranking among five
variant callers examined in hybridization capture-based
exome sequencing largely holds true for PCR-based
amplicon sequencing. Amplicon sequencing can achieve
much higher variant detection sensitivity for low-allelic-
fraction SNVs. At the same time, default variant calling
settings should be further tuned to dampen false positive
rates when analyzing amplicon sequencing data.
Regarding individual algorithms, MuTect and Strelka
show similarly high sensitivity in detecting low-allelic-
fraction SNVs in amplicon sequencing reads, with good
specificity. For high-allelic-fraction somatic SNVs, VarS-
can2 and SomaticSniper perform slightly better than
MuTect and Strelka in terms of sensitivity in both ampli-
con sequencing and exome sequencing data.
NaiveSubtract is very straightforward in concept. Using
NaiveSubtract, variants detected in the tumor but not the
normal sample would be considered putative somatic mu-
tations. Early studies applied such a subtraction method in
detecting somatic mutations and demonstrated success to
some extent [12]. One drawback of NaiveSubtract is that it
does not take into account the complexity of germline false
positives due to PCR-based enrichment artifacts or se-
quencing errors, or false negatives due to under-sampling
during enrichment. Also, NaiveSubtract is not tailored to
handle detection of allele sites with low fraction. In other
words, the sensitivity is limited by the actual variant caller
used, which, in this case, is GATK UnifiedGenotyper.
The performance of VarScan2 is closely related to the
minimum allele fraction threshold, because VarScan2
will suppress any mutations below this threshold. We
could improve VarScan2 sensitivity after tuning the
minimum allele fraction cut-off from the default 0.20 to
a lower value, but at the cost of significantly compro-
mised specificity (data not shown). In one recent study
[16], VarScan2 achieved a sensitivity of 0.97 for detecting
variants of 5% fraction in targeted sequencing with aver-
age coverage of >1000×. However, the false positive rate
in this study was 59 per Mb after the poor quality, low
coverage, and germline sites were masked, which is
about 3-fold higher than our results. Furthermore, prior
knowledge about tumor purity is unavailable in real-
world applications, so users often use default settings to
run VarScan2. Using the default VarScan2 settings, we
were unable to call somatic SNVs of low allelic fraction.
Although we set the parameters to maximize sensitiv-
ity, Somatic Sniper’s performance still falls behind other
algorithms in calling somatic SNVs of low allelic frac-
tion. However, SomaticSniper did achieve the highest
sensitivity in the 100% ‘pure tumor’-normal match. The
low sensitivity of VarScan2 and SomaticSniper in calling
low-allelic-fraction somatic SNVs is consistent with the
results in [17], which showed sensitivity less than 0.10
for somatic SNVs of fraction lower than 0.20. In
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somatic SNV candidates for any level of allele fraction:
MuTect and Strelka can robustly detect somatic SNVs at
low allelic fraction, with an average sensitivity of 0.89
and 0.86 for sites above 0.05 allelic fraction, respectively.
The merits of using artificial matched tumor-normal
sample mixture series data sets created for calling
NA12878 “somatic” SNVs are at least two-fold: (1)
the NIST-GIAB gold-standard is a well-defined, high-
confidence, large set of SNVs for benchmark evaluation,
and (2) this setup allowed us to assess variant calling for
somatic SNVs of a wide range of allele fractions from
real data. The advantages of the NIST-GIAB gold stand-
ard lie in the fact that more sites could be assessed as
compared to SNP arrays, which are normally limited to
common variants. However, one limitation of our ana-
lysis is that a high-confidence variant list for the back-
ground germline variants is not available. Therefore,
using NA12878 for an artificial “somatic” sample is
likely more accurate in evaluating sensitivity than in
evaluating specificity. Another limitation is that the
NA12878 DNA purchased from Coriell is not exactly
the same batch used for the NIST-GIAB variant calls. In
addition, one constraint of our artificial matched nor-
mal samples is the unmatched error distribution be-
tween the “normal” and “tumor” samples. So the virtual
tumor-normal matches would potentially reduce the
performance of methods relative to performance on real
tumor samples that have error distributions more simi-
lar to the matched normal sample.
In principle, characterizing how performance of differ-
ent methods depends on factors such as allele fraction
is necessary for designing experiments. The complexity
and systematic noise from sequencing from tumor-
normal matched samples affect each algorithm, but does
so in different ways. For systematic comparison, here we
used the same aligned read file for all the methods,
whereas impact of aligners on the methods would fur-
ther distinguish their performance. Deeper understand-
ing of the sample properties and the ultimate goals of a
cancer research project will make a difference in the
choice of algorithms. This work can be extended to ad-
dress questions regarding detecting variants from small
amount of target genome mixed in the control samples.
Our work provides insights for the community to assist
in choosing sensitive and specific methods for somatic
SNV calling, given a specific set of data type and experi-
mental conditions.
Conclusions
In this work, we demonstrated that the five somatic
SNV calling methods are applicable to both matched
tumor-normal targeted amplicon and exome sequencing
data. Sensitivities vary with allelic fraction of themutation in the tumor sample. Our results show
MuTect and Strelka achieved the highest sensitivities.
Our analysis can assist researchers in choosing a somatic
SNV calling method for their specific needs.
Methods
Virtual tumor-normal targeted amplicon sequencing data
DNA samples of NA12878 and NA19129 were pur-
chased from Coriell Institute. Sample mixtures were cre-
ated based on the actual amplifiable DNA in each
sample, resulting in 0%, 8%, 16%, 36%, and 100% of
NA12878 sample mixed in the NA19129 sample, re-
spectively. We treated the mixed samples at 8%, 16%,
36%, and 100% as the virtual tumor samples and the 0%
as the virtual normal sample. Therefore, we produced
artificially matched tumor-normal samples to call som-
atic SNVs. QIAGEN’s GeneRead DNAseq Comprehen-
sive Cancer Gene Panel (Version 1) was used to amplify
the target region of interest (124 genes, 800 Kb). Targeted
enrichment and library construction were done following
manufacturer’s user manual (QIAGEN). Briefly, 160 ng of
each virtual tumor sample or virtual normal sample were
PCR amplified and purified. For each sample, one quarter
of the PCR product was used for constructing a barcoded
Illumina DNA library. Libraries were quantified using
QIAGEN’s GeneRead DNAseq Library Quant System, and
were mixed in equal amount. Illumina MiSeq sequencing
was performed following manufacturer’s user manual
(Illumina) to generate FASTQ files, resulting in median
coverage depth of 500–700x for each sample. Experiments
were performed in triplicate. The sequencing reads were
aligned to the reference genome using BWA [24], then
preprocessed according to Broad best practice guidance
(indel realignment, base quality score recalibration, and
base alignment quality scoring). Finally, the primer se-
quences were trimmed away from the pre-processed reads
before variant calling.
Virtual tumor-normal whole exome sequencing data
Whole exome sequencing data of NA12878 and NA18489
were obtained from the 1,000 Genomes Project [25]. Raw
reads were mapped to the hg19 human reference genome
sequence (GRCh37) by the 1,000 Genomes Project. The
publicly available read alignment files in BAM format were
generated with BWA mapping, GATK local realignment
around known indels, GATK base quality score recalibra-
tion, and Picard MarkDuplicates. Each BAM file was ran-
domly downsampled using Picard command-line tools
with various percentages to achieve the following mixture
concentrations: 8%, 16%, 36%, and 50%. One NA12878
downsampled result and one NA18489 downsampled re-
sult were then merged using SAMtools [26]. This step was
repeated for different mixture percentages to create an in
silico dilution series. Consequently, the primary NA18489
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and the NA12878 dilution series were treated as the
matched virtual tumor samples.
Region of interest
For targeted amplicon sequencing data, the region of
interest (ROI) includes 661,684 bases, resulting from the
intersection between QIAGEN CCP panel regions and
NIST-GIAB high-confidence callable regions (Version
2.15, excluding genomic sites with conflicting genotype
evidence, repetitive regions, decoy sequences, or reported
structural variants, as well as regions/variant locations with
evidence of bias (systematic sequencing errors, local align-
ment bias, etc.)), plus masking 213 bp of NA19129 variant
sites annotated by 1,000 Genomes Project (ftp://ftp-trace.
ncbi.nih.gov/1000genomes/ftp/release/20110521/). For ex-
ome sequencing data, the region of interest include
33,886,321 bases, resulting from the intersection between
the exome capture regions with at least one read coverage
in both samples and the NIST-GIAB high-confidence sites,
plus masking 12,974 bp of NA18489 variant sites anno-
tated by 1,000 Genomes Project (ftp://ftp-trace.ncbi.nih.
gov/1000genomes/ftp/release/20110521/). For these re-
gions of interest, the NIST-GIAB gold standard contains a
181 and 9,868 ‘somatic’ SNVs for our targeted-sequencing
and exome-sequencing evaluation, respectively (for details
see Additional file 1: Table S1).
Variant calling algorithms
Altogether, we included the following methods for com-
parison (for corresponding command lines for calling
the five algorithms, see Additional file 1):
1. NaiveSubtract — SNVs were called separately from
virtual tumor and normal samples using GATK
UnifiedGenotyper [22]. For exome sequencing data,
reads were already mapped, locally realigned and
recalibrated by the 1,000 Genomes Project. So SNVs
were directly called on the BAM files using GATK
Unified Genotyper. Then, SNVs detected in the
virtual normal sample were removed from the list of
SNVs detected in the virtual tumor sample, leaving
the “somatic” SNVs.
2. MuTect — MuTect is a method developed for
detecting the most likely somatic point mutations in
NGS data using a Bayesian classifier approach. The
method includes pre-processing aligned reads separately
in tumor and normal samples and post-processing
resulting variants by applying an additional set of
filters. We ran MuTect under the High-Confidence
mode with its default parameter settings. We disabled
the “Clustered position” filter and the “dbSNP filter”
for the amplicon sequencing reads, and we disabled
the “dbSNP filter” for the exome sequencing.3. SomaticSniper — SomaticSniper calculates the
Bayesian posterior probability of each possible joint
genotype across the normal and cancer samples. We
tuned the software’s parameters to increase
sensitivity and then filtered raw results using a
Somatic Score cut-off of 20 to improve specificity.
4. Strelka — Strelka reports the most likely genotype
for tumor and normal samples based on a Bayesian
probability model. Post-calling filters built into the
software are based on factors such as read depth,
mismatches, and overlap with indels. We skipped
depth filtration for exome and amplicon sequencing
data as recommended by the Strelka authors. For
the amplicon sequencing reads, we set the minimum
MAPQ score at 17 for consistency with the defaults
in GATK UnifiedGenotyper. We used variants
passing Strelka post-calling filters for analysis.
5. VarScan2 — VarScan2 performs analyses
independently on pileup files from the tumor and
normal samples to heuristically call a genotype at
positions achieving certain thresholds of coverage
and quality. Then, sites of the genotypes not
matched in tumor and normal samples are classified
into somatic, germline, or ambiguous groups using
Fisher’s exact test. We generated the pileup files
using SAMtools mpileup command.
The compatibility of the output VCF files between dif-
ferent methods as well as the NIST-GIAB gold standard
was examined using bcbio.variation tools and manual in-
spection. The reported SNP call representations between
files are comparable to each other.
Performance metrics
We used sensitivity and false positive rate as the per-
formance metrics:




False Postive Rate per Mbð Þ ¼ FP
FP þ TN  10
6
Availability of supporting data
The command line scripts of variant calling algorithms
we used in the paper are included in the additional files.
Additional file
Additional file 1: Supplementary Tables and Supplementary Methods.
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